Tuesday, April 16, 2024

JYNNEOS® Mpox Vaccine Now Commercially Available in the U.S. Through Bavarian Nordic’s Nationwide Launch

Similar articles

Bavarian Nordic A/S, recognized on the OMX stock exchange as BAVA, has proudly announced the commercial release of JYNNEOS®, the exclusive FDA-approved mpox vaccine, now available across the United States. This significant development broadens the scope of access to JYNNEOS® by introducing diversified avenues for the mpox vaccine’s procurement, distribution, and financial coverage, accessible through both public and private insurance entities.

The commercial availability marks a pivotal expansion in the mpox vaccine’s accessibility, building upon the existing framework that facilitated JYNNEOS® distribution via public health mechanisms to individuals identified at an increased risk of contracting mpox. This strategic distribution was enabled by Bavarian Nordic’s longstanding collaboration with the U.S. government, aimed at bolstering the national vaccine stockpile, and was underpinned by interim guidelines issued by the Centers for Disease Control and Prevention (CDC).

These guidelines advocated for both pre- and post-exposure vaccination during the mpox outbreak, a stance solidified in October 2023 following a unanimous endorsement by the CDC’s Advisory Committee on Immunization Practices (ACIP) for the routine administration of JYNNEOS® to adults over 18 years of age with specified risk factors.

Persistent Mpox Spread in U.S. Amidst Low Vaccination Rates Spurs Bavarian Nordic’s JYNNEOS® Commercial Launch

Despite the de-escalation of mpox from a public health emergency status, the United States continues to witness ongoing transmissions, with reports indicating an average of 200 new cases each month throughout 2024, highlighting the virus’s persistent spread across the majority of states. Since the outbreak’s inception in 2022, the U.S. has documented over 32,000 mpox cases, signifying a third of the global case count.

Current CDC data estimates indicate that approximately two million individuals in the U.S. are eligible for the mpox vaccination, yet a significant portion of this demographic remains unprotected, with 60% completely unvaccinated and an additional 15% having received only one dose of the vaccine. Evidence suggests that individuals who complete the recommended two-dose vaccination regimen exhibit superior protection against mpox compared to those who are partially vaccinated or not vaccinated at all.

Bavarian Nordic’s initiative to make JYNNEOS® commercially available represents a critical step forward in the company’s commitment to public health. Starting April 1, healthcare providers have been able to order JYNNEOS® through their preferred wholesalers and distribution partners, facilitating access to the mpox vaccine in local pharmacies, physician offices, and public health clinics nationwide.

Mpox Vaccine

Leaders Laud JYNNEOS® Mpox Vaccine Rollout as Milestone in Mpox Prevention and Healthcare Equity

Paul Chaplin, President and CEO of Bavarian Nordic, expressed pride in the company’s efforts to mitigate the impact of mpox since the outbreak nearly two years ago. He emphasized the crucial role of the approved mpox vaccine and a robust public health response in controlling the disease’s spread, despite the virus’s ongoing presence. Chaplin reiterated Bavarian Nordic’s dedication to improving public health in the U.S. by ensuring that the mpox vaccine is widely available through conventional channels, thereby strengthening the nation’s defense against this disease.

Echoing the significance of this development, Brian Hujdich, Executive Director of the National Coalition for LGBTQ Health, highlighted the expanded availability of JYNNEOS® as a key advancement in promoting equitable healthcare access for the LGBTQ+ community and a major leap in preventing the spread of mpox. Hujdich called for continued advocacy for inclusive health policies that safeguard and enhance the well-being of all communities, urging at-risk individuals to consult healthcare providers about vaccination.

In closing, comprehensive information about mpox and the JYNNEOS® vaccine, including disease background, vaccine details, eligibility criteria, and safety information, is readily available on the CDC and Bavarian Nordic websites, providing essential resources for individuals seeking to learn more about this critical public health tool.

 

Resource: Bavarian Nordic, April 02, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article